Form 4: Joseph Malchow sells warrants issued July 2025 (ENVXW)

Rhea-AI Filing Summary

Enovix Corp director Joseph Ian Malchow reported sales of publicly traded warrants issued July 21, 2025. The Form 4 shows warrants (exercise price $8.75) that were distributed to the reporting person at no cost were sold in the public market on 08/15/2025 at prevailing market prices. The filing lists three warrant lots sold: 58,437; 628; and 185 warrants, each exercisable into one share of common stock and expiring on 10/01/2026 (subject to early acceleration conditions). Holdings following the transactions are reported as 0 shares for the sold warrants; some underlying shares were held jointly with spouse and by a minor child.

Positive

• Clear regulatory disclosure: Form 4 documents the director's warrant sales and ownership details, meeting Section 16 reporting requirements.
• Detailed transaction data provided: Dates (07/21/2025 distribution; 08/15/2025 sales), quantities (58,437; 628; 185), strike ($8.75), and expiration (10/01/2026) are all specified.

Negative

• Insider disposition: The reporting person sold all reported warrants (resulting in 0 beneficial ownership of those warrant positions after the transactions).

Insights

Corporate Governance Expert

TL;DR: Director sold distributed warrants publicly; filing documents the transaction and remaining ownership status.

The Form 4 discloses transparent compliance with Section 16 reporting for a director-level issuer insider. The warrants were initially distributed at no cost on 07/21/2025 and carried an $8.75 exercise price. Sales executed 08/15/2025 removed the reported warrant positions (58,437; 628; 185), with zero beneficial ownership of those warrants after the trades. The filing also clarifies that some resulting shares are held jointly with a spouse and a minor child, indicating mixed direct and indirect holdings. This is a routine insider disposition disclosure rather than a corporate action.

Securities Analyst

TL;DR: Material details show timing, quantities, and exercise terms; impact appears informational rather than balance-sheet changing.

The filing provides concrete transaction data: warrants exercisable into one share each, $8.75 strike, expiration 10/01/2026, sold on 08/15/2025 in the public market. Quantities sold are explicitly stated (58,437; 628; 185). The report was signed by an attorney-in-fact on 08/22/2025. From a market impact perspective, the document records insider sales of distributed warrants but contains no information about company operations, earnings, or changes to capitalization beyond the warrant detail.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malchow Joseph Ian

(Last) (First) (Middle)

C/O ENOVIX CORPORATION

3501 W WARREN AVENUE

(Street)

FREMONT CA 94538

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enovix Corp [ ENVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant (Right to Buy)	$8.75	08/15/2025		S			58,437(1)	07/21/2025	10/01/2026(2)	Common Stock, par value $0.0001	58,437	$1.7(3)	0	D
Warrant (Right to Buy)	$8.75	08/15/2025		S			628(1)	07/21/2025	10/01/2026(2)	Common Stock, par value $0.0001	628	$1.7(3)	0	D(4)
Warrant (Right to Buy)	$8.75	08/15/2025		S			185(1)	07/21/2025	10/01/2026(2)	Common Stock	185	$1.7(3)	0	I(5)	Shares held by a minor child.

Explanation of Responses:

1. This Form 4 relates to sales of publicly-traded warrants (the "Warrants") previously distributed to the Reporting Person. The Warrants were distributed by the Issuer on July 21, 2025 at no cost to the Reporting Person, and each Warrant entitles the holder to purchase one share of common stock at an exercise price of $8.75 per share in accordance with the Warrant Agreement dated July 21, 2025 between the Issuer and Computershare Trust Company N.A., as warrant agent (the "Warrant Agreement").

2. The Warrants will expire and cease to be exercisable at 5:00 p.m. New York City time on October 1, 2026 (the Expiration Date). The Expiration Date is subject to automatic acceleration upon satisfaction of the early expiration price condition (as defined in the Warrant Agreement) and subject to the other terms of the Warrant Agreement.

3. The Warrants were sold on August 15, 2025 in the public market and at the prevailing market price.

4. Shares held by Reporting Person and spouse JTWROS.

5. Shares held by a minor child.

Remarks:

	/s/ Arthi Chakravarthy, Attorney-in-Fact for Joseph Malchow	08/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Joseph Ian Malchow report selling for Enovix (ENVXW)?

He reported sales of publicly traded warrants that were distributed to him on 07/21/2025; the sales occurred on 08/15/2025.

How many warrants did the reporting person sell and what are the terms?

The Form 4 lists sales of 58,437, 628, and 185 warrants; each warrant has an $8.75 exercise price and expires on 10/01/2026.

Were the warrants sold at a negotiated price or market price?

The filing states the warrants were sold in the public market on 08/15/2025 at the prevailing market price.

Does the Form 4 show any remaining beneficial ownership of the sold warrants?

No; the filing reports 0 warrants beneficially owned following the reported transactions for the sold warrant positions.

Who signed the Form 4 for Joseph Malchow?

The Form 4 was signed by Arthi Chakravarthy, Attorney-in-Fact for Joseph Malchow on 08/22/2025.